Skip to Content

Ryman Healthcare Ltd - Stock Quote RYM

Rating as of

Morningstar's Ryman Healthcare Ltd Stock Analysis

Currency in NZD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


A Strong 2022 for Ryman, and Set to Keep Growing in 2023; NZD 15.20 FVE Maintained, Securities Are Cheap

Alexander Prineas Equity Analyst

Analyst Note

| Alexander Prineas |

A strong result from narrow-moat Ryman Healthcare reaffirmed our thesis the stock is considerably undervalued. Fiscal 2022 underlying net profit exceeded our estimate of NZD 209 million, growing 14% to NZD 255 million (NZD 0.51 per security). Dividends were NZD 22.4 cents per security, in line with fiscal 2021, and in line with our 2022 estimate.

Read Full Analysis

Ryman Healthcare Ltd's Company Profile

Business Description

Ryman Healthcare develops, owns, and operates retirement villages and aged care facilities in New Zealand and Australia. Most Ryman villages offer a combination of independent and serviced units, alongside hospital, dementia, and rest-home care. Income is predominantly earned from aged care fees, retirement unit management fees, development margins on new units, and capital gains generated when residents vacate and Ryman resells existing units.

92 Russley Road, P.O. Box 771
Christchurch, 8042, New Zealand
T +64 33664069
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings
Fiscal Year End Mar 31, 2022
Stock Type